These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 37576392)
41. High SNRPA1 expression leads to poor prognosis in patients with lung adenocarcinoma. Yang JJ; Yang YJ; Gu YL; Tong L; Liu YF; Zhang JG Clin Respir J; 2023 Aug; 17(8):719-732. PubMed ID: 37277111 [TBL] [Abstract][Full Text] [Related]
42. Integrated analyzes identify CCT3 as a modulator to shape immunosuppressive tumor microenvironment in lung adenocarcinoma. Huang J; Hu B; Yang Y; Liu H; Fan X; Zhou J; Chen L BMC Cancer; 2023 Mar; 23(1):241. PubMed ID: 36918801 [TBL] [Abstract][Full Text] [Related]
43. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis. Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ Front Immunol; 2021; 12():724741. PubMed ID: 34335635 [TBL] [Abstract][Full Text] [Related]
44. Comprehensive Analysis of Immune Implication and Prognostic Value of Zeng Y; Zhang Z; Chen H; Fan J; Yuan W; Li J; Zhou S; Liu W Front Oncol; 2021; 11():798425. PubMed ID: 35047409 [TBL] [Abstract][Full Text] [Related]
45. ITGB4 is a prognostic biomarker and correlated with lung adenocarcinoma brain metastasis. Zhang J; Li L; Luo W; Ma S; Zhao Y Clin Transl Oncol; 2024 Dec; 26(12):2979-2992. PubMed ID: 38776034 [TBL] [Abstract][Full Text] [Related]
46. Chen P; Quan Z; Song X; Gao Z; Yuan K Front Oncol; 2022; 12():1005962. PubMed ID: 36300089 [TBL] [Abstract][Full Text] [Related]
47. The downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinoma via regulating Tang XY; Xiong YL; Shi AP; Sun Y; Han Q; Lv Y; Shi XG; Frattini M; Malhotra J; Zheng KF; Liu YJ; Jiang T; Ma N; Zhao JB Transl Lung Cancer Res; 2022 Mar; 11(3):404-419. PubMed ID: 35399566 [TBL] [Abstract][Full Text] [Related]
48. SLC7A5 is a lung adenocarcinoma-specific prognostic biomarker and participates in forming immunosuppressive tumor microenvironment. Liu Y; Ma G; Liu J; Zheng H; Huang G; Song Q; Pang Z; Du J Heliyon; 2022 Oct; 8(10):e10866. PubMed ID: 36217463 [TBL] [Abstract][Full Text] [Related]
49. NcRNA-Mediated High Expression of Jiang X; Tang L; Yuan Y; Wang J; Zhang D; Qian K; Cho WC; Duan L Front Oncol; 2022; 12():846536. PubMed ID: 35311097 [TBL] [Abstract][Full Text] [Related]
50. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma. Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ Front Genet; 2022; 13():1017866. PubMed ID: 36699466 [No Abstract] [Full Text] [Related]
51. Identification of a prognostic classifier based on EMT-related lncRNAs and the function of LINC01138 in tumor progression for lung adenocarcinoma. Xiao L; Huang Y; Li Q; Wang S; Ma L; Fan Z; Tang Z; Yuan X; Liu B Front Mol Biosci; 2022; 9():976878. PubMed ID: 36060239 [No Abstract] [Full Text] [Related]
52. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma. Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J Front Immunol; 2023; 14():1217590. PubMed ID: 37492563 [TBL] [Abstract][Full Text] [Related]
53. Vesicle-mediated transport-related genes are prognostic predictors and are associated with tumor immunity in lung adenocarcinoma. Qian C; Jiang Z; Zhou T; Wu T; Zhang Y; Huang J; Ouyang J; Dong Z; Wu G; Cao J Front Immunol; 2022; 13():1034992. PubMed ID: 36524130 [TBL] [Abstract][Full Text] [Related]
54. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma. Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573 [TBL] [Abstract][Full Text] [Related]
55. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma. Chang W; Li H; Cheng Y; He H; Ou W; Wang SY Front Immunol; 2023; 14():1171145. PubMed ID: 37081889 [TBL] [Abstract][Full Text] [Related]
56. Identification of a Three-Gene Signature Based on Epithelial-Mesenchymal Transition of Lung Adenocarcinoma Through Construction and Validation of a Risk-Prediction Model. Shi J; Wang Z; Guo J; Chen Y; Tong C; Tong J; Hu W; Li C; Li X Front Oncol; 2021; 11():726834. PubMed ID: 34745947 [TBL] [Abstract][Full Text] [Related]
57. An integrated analysis of prognostic and immune infiltrates for hub genes as potential survival indicators in patients with lung adenocarcinoma. Xu Z; Wang S; Ren Z; Gao X; Xu L; Zhang S; Ren B World J Surg Oncol; 2022 Mar; 20(1):99. PubMed ID: 35354488 [TBL] [Abstract][Full Text] [Related]
58. AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma. Ma C; Kang W; Yu L; Yang Z; Ding T Front Oncol; 2020; 10():590006. PubMed ID: 33363020 [TBL] [Abstract][Full Text] [Related]
59. Wu C; Dong B; Huang L; Liu Y; Ye G; Li S; Qi Y Front Oncol; 2021; 11():754290. PubMed ID: 34745988 [TBL] [Abstract][Full Text] [Related]
60. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma. Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]